Inner Quaternary Ammonium Salt (e.g., Betaine, Etc.) Patents (Class 514/556)
  • Patent number: 10624365
    Abstract: The present invention relates to a composition containing medium-chain fatty acids or salts or mono-, di-, triglycerides, esters or amides derivatives of medium-chain fatty acids for use as a feed additive for animals, in an optimized ratio. In a second and third aspect, the invention concerns an animal feed, supplemented with the composition containing the medium-chain fatty acids or derivatives and a method for feeding animals with the animal feed.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: April 21, 2020
    Assignee: Nutrition Sciences N.V.
    Inventors: Geert Bruggeman, Katrien Deschepper
  • Patent number: 10576125
    Abstract: Disclosed here is a method for enhancing synaptogenesis and/or neuritogenesis, reducing neurodegeneration, and/or reducing accumulation or aggregation of Tau proteins in a subject suffering from cochlear synaptopathy or vestibular synaptopathy or a central nervous system disease or condition, comprising administering to said subject in need thereof an effective amount of 2,4-disulfonyl ?-phenyl tertiary butyl nitrone (2,4-DSPBN) or a pharmaceutically acceptable salt thereof. The method may further comprise administrating N-acetylcysteine (NAC) to the subject.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 3, 2020
    Assignee: Hough Ear Institute
    Inventors: Richard D. Kopke, Wei Li
  • Patent number: 9463160
    Abstract: A rapidly dispersing dosage form is described. The dosage form releases its active ingredients within a period of less than about ninety seconds. These dosage forms exhibit a three-dimensional shape that is retained for adequate storage but is readily dispersed in the presence of excess moisture. Also disclosed are methods of administration of a medicament and a process for the preparation of rapidly dispersing dosage forms.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: October 11, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Jaedeok Yoo, Sandeep Kumar, Donald C. Monkhouse
  • Patent number: 9271953
    Abstract: The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 1, 2016
    Assignee: GENETIC DISEASE INVESTIGATORS, LLC
    Inventor: Diana Driscoll
  • Patent number: 9114120
    Abstract: It is described the use of L-carnitine and/or one or more alkanoyl L-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts, for the preparation of a medicament or a nutritional supplement useful for preventing or treating the Leber optic neuropathy.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 25, 2015
    Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE, S.P.A.
    Inventors: Aleardo Koverech, Stefania D'Iddio, Anna Atti, Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza
  • Patent number: 8969413
    Abstract: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: March 3, 2015
    Assignees: Catalyst Pharmaceutical Partners, Brookhaven Science Associates, Northwestern University
    Inventors: Richard B. Silverman, Stephen L. Dewey, Steven Miller
  • Publication number: 20150045432
    Abstract: A palatable, single serving dietary supplement of amino acids that may be taken as a nutritional aid to improve health and well-being by promoting higher quality sleep, enhancing repair of muscular tissue after strenuous exercise in part through boosting the natural production of human growth hormone, enhancing the immune system, improve gut barrier function, aiding in responses to upper respiratory viral pathogens, reversing side effects from the over use of nutritional energy drinks with stimulants and simple sugars and reverse the side effects of excess signaling through the cortisol pathway resulting from chronic environmental stress.
    Type: Application
    Filed: May 6, 2014
    Publication date: February 12, 2015
    Applicant: North Health Essentials, LLC
    Inventors: Robert North, James Crute
  • Patent number: 8952059
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 10, 2015
    Assignee: Sigma-Tau Industrie Faramceutiche Riunite S.p.A.
    Inventors: Antonino Amato, Menotti Calvani
  • Patent number: 8940792
    Abstract: An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The composition can be applied directly to a site of bacterial growth. Even when the bacteria is in biofilm form, the surfactant component(s) begin to kill the bacteria before the macromolecular matrix is removed or dislodged from the site.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 27, 2015
    Assignee: Next Science, LLC
    Inventor: Matthew Franco Myntti
  • Patent number: 8940793
    Abstract: 4-[(Haloalkyl)(dimethyl)ammonio]butanoates of formula wherein Hal is Cl or F, n=1 or 2, method for preparing thereof and use thereof for treating cardiovascular disease.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: January 27, 2015
    Assignee: JSC Grindeks
    Inventors: Ivars Kalvins, Edgars Liepins, Einars Loza, Maija Dambrova, Ilmars Stonans, Daina Lola, Janis Kuka, Osvalds Pugovics, Viktors Andrianovs, Marina Makrecka, Daina Gustina, Solveiga Grinberga
  • Patent number: 8933245
    Abstract: Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a trimethylamine absorber in an amount sufficient to prevent the detection of any trimethylamine odor by the human nose. A method is further provided for ameliorating the methylamine odor associated with an aqueous ergothioneine-containing preparation after it has developed a fishy trimethylamine odor.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: January 13, 2015
    Assignee: ELC Management LLC
    Inventor: Daniel B. Yarosh
  • Patent number: 8921595
    Abstract: In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: December 30, 2014
    Assignee: University of South Carolina
    Inventors: Paul R. Thompson, Corey P. Causey
  • Publication number: 20140322283
    Abstract: The present invention relates to water-dispersible core-shell microcapsules essentially free of formaldehyde. In particular it concerns core-shell microcapsules having a shell obtained by reacting polyisocyanates or polyoxirans cross-linkers and oligomeric compositions which are the reaction products between a polyamine component and a particular mixture of glyoxal and a C4-6 2,2-dialkoxy-ethanal. The present invention comprises also the invention's core-shell microcapsules as part of a perfuming composition or of a perfuming consumer product.
    Type: Application
    Filed: October 29, 2012
    Publication date: October 30, 2014
    Applicant: FIRMENICH SA
    Inventors: Damien Berthier, Géraldine Leon, Nicolas Paret, Lahoussine Ouali
  • Publication number: 20140308338
    Abstract: A dressing for applying to the skin is characterized in that the adhesive mass is applied discontinuously in a strip or wave and contains an active substance.
    Type: Application
    Filed: August 29, 2012
    Publication date: October 16, 2014
    Applicant: BEIERSDORF AG
    Inventors: Jens Nierle, Karl-Heinz Woeller, Maxi Zier, Gerd Mueller
  • Publication number: 20140286922
    Abstract: A method of measuring the effect of an active agent or a stressor on the baseline metabolic indicators of one or more hair follicles, the method including (a) obtaining one or more hair follicles; (b) placing the one or more hair follicles in a vessel, wherein the one or more hair follicles are positioned under one or more sensors; (c) using the one or more sensors to measure the one or more hair follicles' baseline metabolic indicators for both glycolysis and oxidative phosphorylation; (d) exposing the one or more hair follicles to an active agent or a stressor; and (e) using the one or more sensors to measure the one or more hair follicles' respondent metabolic indicators for both glycolysis and oxidative phosphorylation.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 25, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Ben Charlton HULETTE, Thomas Larry DAWSON, JR.
  • Publication number: 20140228435
    Abstract: The embodiments herein provide a therapeutic composition comprising N (delta)-protonated L-2-amino-5-diaminomethyleneamino-pentanoic acid called J Factor and a method of ex-vivo synthesis of J-Factor from N(omega)?-protonated L-arginine at a pH of 5-9. The method involves increasing a temperature and or decreasing an acidity of an aqueous solution containing the N(omega)?-protonated L-arginine to obtain a pH value of greater than pKa?2 or less than pKa+2. The derivatives of aqueous solution are allowed to reach an equilibrium state at 25° C. The acidity of the acidity of the aqueous solution is adjusted to a pH value of 7.0 at 25° C. The pKa is a minus logarithm of an acid dissociation constant of the N(omega)?-protonated guanidino group. The N(omega)?-protonated 1-arginine includes ionized forms in the carboxyl or 2-amino group, which are in equilibrium with the N(omega)?-protonated 1-arginine. The composition has a molecular mass of more than or equal to 175.
    Type: Application
    Filed: February 13, 2013
    Publication date: August 14, 2014
    Inventor: MEHDI BAKHTIARI
  • Patent number: 8778410
    Abstract: The present invention provides an oral or enteral composition incorporating not only BCAA but other nutrients to be conducive to comprehensive recovery from fatigue, and improvement in total physical condition. The oral or enteral composition is formulated as a composite of a branched-chain amino acid, coenzyme Q10, L-carnitine, a citric acid, and zinc.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: July 15, 2014
    Assignees: Earnest Medicine Co., Ltd., Otsuka Pharmaceutical Factory, Inc.
    Inventors: Takashi Higashiguchi, Takako Hatakeyama
  • Patent number: 8748344
    Abstract: An adjuvant composition contains an adjuvant composition, comprising, based on 100 parts by weight of the composition: (a) from about 10 to 100 parts by weight of a combined of one or more betaine surfactants and one or more glycoside surfactants, comprising, based on 100 parts by weight of the combined amount: (i) from greater than 0 to less than 100 parts by weight of the one or more betaine surfactants, and (ii) from greater than 0 to less than 100 parts by weight of one or more glycoside surfactants, and (b) from 0 to about 90 parts by weight water A pesticide composition contains based on 100 parts by weight of the composition: (a) from greater than 0 parts by weight to about 20 parts by weight of a combined amount of one or more betaine surfactants and one or more glycoside surfactants, comprising, based on 100 parts by weight of the combined amount: (i) from greater than 0 to less than 100 parts by weight of the one or more betaine surfactants, and (ii) from greater than 0 to less than 100 parts by wei
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 10, 2014
    Assignee: Rhodia Operations
    Inventors: Michael Kisenwether, Shanmuganandamurthy Krishnamurthy, Rajesh Pazhianur
  • Patent number: 8729125
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: May 20, 2014
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Patent number: 8703819
    Abstract: The use of guanidinoacetic acid and/or salts thereof in combination with choline and/or betaine to produce an agent for improving brain function, bone growth and the mineralization of bones, for improving cartilage growth, for alleviating aging processes, for strengthening the immune system, as an antioxidative and neuroprotective agent, for lowering the cholesterol and triglyceride value, for preventing inflammatory processes and for lowering the blood sugar level in humans and vertebrates is described. In this connection it has surprisingly turned out that the new agents have a considerably higher bioavailability and are thus better taken up into the cells than was previously known when using creatine.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: April 22, 2014
    Assignee: Alzchem Trostberg GmbH
    Inventors: Thomas Gastner, Hans-Peter Krimmer
  • Publication number: 20140107201
    Abstract: The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use.
    Type: Application
    Filed: April 4, 2012
    Publication date: April 17, 2014
    Applicant: LONZA LTD.
    Inventors: Adriana Williams, Frauke Warrikoff, Ulla Freitas, Richard Sasse, Kevin Owen
  • Publication number: 20140107560
    Abstract: Solubilizing compositions are provided. The compositions comprise at least one zwitterionic surfactant and at least one nonionic surfactant. In one embodiment, the compositions may be useful for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin, optionally in conjunction with the application of energy to a region of interest on the skin. In one embodiment at least one analyte may be collected and analyzed from the solubilized tissue.
    Type: Application
    Filed: December 22, 2013
    Publication date: April 17, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Samir Mitragotri, Russell M. Lebovitz, Byeong Hee Hwang
  • Publication number: 20140107202
    Abstract: 4-[(Haloalkyl)(dimethyl)ammonio]butanoates of formula wherein Hal is Cl or F, n=1 or 2, method for preparing thereof and use thereof for treating cardiovascular disease.
    Type: Application
    Filed: April 27, 2012
    Publication date: April 17, 2014
    Applicant: JSC GRINDEKS
    Inventors: Ivars Kalvins, Edgars Liepins, Einars Loza, Maija Dambrova, Ilmars Stonans, Daina Lola, Janis Kuka, Osvalds Pugovics, Viktos Andrianovs, Marina Makrecka, Daina Gustina, Solveiga Grinberga
  • Publication number: 20140080907
    Abstract: The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 20, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventor: Young Chul Kim
  • Publication number: 20140056862
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and ?-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 27, 2014
    Applicant: Nestec S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140056863
    Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid eicosapentaenoic acid. It may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, ?-ketoglutarate, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: February 27, 2014
    Applicant: Nestec S.A.
    Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
  • Publication number: 20140051757
    Abstract: It is described the use of L-carnitine and/or one or more alkanoyl L-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts, for the preparation of a medicament or a nutritional supplement useful for preventing or treating the Leber optic neuropathy.
    Type: Application
    Filed: September 9, 2011
    Publication date: February 20, 2014
    Applicant: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Silvia Cavazza, Martina Cavazza, Francesca Cavazza, Anna Atti, Enrico Cavazza
  • Publication number: 20140045939
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: September 11, 2013
    Publication date: February 13, 2014
    Applicant: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Publication number: 20140045773
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: September 11, 2013
    Publication date: February 13, 2014
    Applicant: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Publication number: 20140024712
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 23, 2014
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Antonino AMATO, Menotti CALVANI
  • Publication number: 20140024711
    Abstract: An antimicrobial cleansing composition including (a) 20 to less than 60 wt. % of at least one alcohol selected from ethanol and propanol; (b) 0.5 to 10 wt. % of a surfactant selected from sulfate salt surfactants and amphoteric surfactants. The composition shows effective cleansing and antimicrobial properties. Hence, using this composition, it will no longer be required to provide in hospitals two separate dispensers one for foam soap and one for antimicrobial alcohol-based composition. The antimicrobial cleansing composition can be used for making foam. Also, a dispenser contains the above antimicrobial cleansing composition.
    Type: Application
    Filed: March 8, 2011
    Publication date: January 23, 2014
    Applicant: SCA HYGIENE PRODUCTS AB
    Inventors: Torsten Hedbom, Stefan Snell
  • Publication number: 20130345171
    Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.
    Type: Application
    Filed: June 11, 2013
    Publication date: December 26, 2013
    Inventors: Stanley L. Hazen, Bruce Levison, Zeneng Wang
  • Patent number: 8614343
    Abstract: The present invention discloses a process for the production of a fatty acid/L-carnitine derivative, whereby the educts are reacted in the presence of monochloroacetic acid.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: December 24, 2013
    Assignee: Lonza Ltd.
    Inventor: Donya Smida
  • Publication number: 20130302389
    Abstract: The present invention relates to a cosmetic composition, which comprises a combination of at least two osmolytes chosen from the group comprising taurine or a derivative thereof, inositol, betaine and trehalose. This composition is intended for restoring, maintaining or reinforcing the moisturization of the skin and/or for protecting it against different types of stress and/or for preventing or retarding the appearance of the signs of aging of the skin, or for attenuating the effects thereof, or alternatively for promoting cell or tissue longevity.
    Type: Application
    Filed: July 17, 2013
    Publication date: November 14, 2013
    Inventors: Marc Dumas, Valerie Krzuch, Delphine Pelle de Queral, Catherine Heusele
  • Patent number: 8575171
    Abstract: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: November 5, 2013
    Inventor: Linzy O. Scott, III
  • Patent number: 8569368
    Abstract: Methods for increasing the bioabsorption of amino acids and for preventing the development of nitrate tolerances in a human or animal are disclosed. The methods include administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: October 29, 2013
    Assignee: Thermolife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 8569369
    Abstract: A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: October 29, 2013
    Assignee: Thermolife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 8569370
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Patent number: 8569367
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Patent number: 8569366
    Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.
    Type: Grant
    Filed: April 26, 2005
    Date of Patent: October 29, 2013
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Antonino Amato, Menotti Calvani
  • Publication number: 20130273165
    Abstract: Subject of the invention is a method for the production of a carnitine granulate, which includes the steps of (a) providing an aqueous solution comprising at least 65% (w/w) carnitine, (b) providing a particulate carrier comprising silica, the carrier having an average particle size of more than 150 ?m, and (c) mixing the aqueous solution and the carrier. Another subject of the invention is a carnitine granulate.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 17, 2013
    Applicant: LONZA LTD.
    Inventor: Thomas Buchner
  • Publication number: 20130272922
    Abstract: An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The composition can be applied directly to a site of bacterial growth. Even when the bacteria is in biofilm form, the surfactant component(s) begin to kill the bacteria before the macro-molecular matrix is removed or dislodged from the site.
    Type: Application
    Filed: March 20, 2013
    Publication date: October 17, 2013
    Inventor: Matthew Franco Myntti
  • Publication number: 20130252945
    Abstract: An amorphous formulations of a pharmaceutical includes a composition of the formula [A]x[MpClq]y, the composition being an ionic liquid with a melting temperature below 150° C., wherein [MpClq] is a metal chloride, x is 1, 2, 3, or 4, p is 1, 2, 3, or 4, q is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and y is 1 or 2, wherein each A is a cation that is a pharmaceutical or a cation precursor that is a pharmaceutical.
    Type: Application
    Filed: March 25, 2013
    Publication date: September 26, 2013
    Inventors: Katherine Lovejoy, Rico Del Sesto, Andrew Koppisch
  • Patent number: 8530412
    Abstract: The present invention provides a liquid composition, as an ejection liquid used for stably ejecting liquid droplets, including at least one kind of a protein and a peptide, and a compound having a betaine skeleton by application of thermal energy to the liquid; a method of making droplets form the liquid; and an ejection method and an ejection device suitable for utilizing protein liquid droplets. By adding a compound having a betaine skeleton to an aqueous solution of at least one kind of a protein and a peptide, the liquid composition is improved in stability for ejection by application of thermal energy. Further, a surfactant may be further added to the liquid composition containing the compound having a betaine skeleton, and in this case the effect of stable ejection can be obtained.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: September 10, 2013
    Assignee: Canon Kabushiki Kaisha
    Inventors: Masaru Sugita, Yohei Masada, Hideki Kaneko
  • Publication number: 20130203848
    Abstract: The invention, described herein, is directed to the use of acetyl. L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in winch said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.
    Type: Application
    Filed: June 10, 2011
    Publication date: August 8, 2013
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Mariagrazia Grilli, Pier Luigi Canonico, Aleardo Koverech
  • Publication number: 20130190398
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 25, 2013
    Applicant: ALLERGAN, INC.
    Inventor: Allergan, Inc.
  • Patent number: 8486916
    Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: July 16, 2013
    Assignee: Megmilk Snow Brand Co., Ltd.
    Inventors: Ken Kato, Susumu Miura, Leo Tanaka, Hiroshi Ueno, Noriko Ueda, Yuko Haruta, Toshimitsu Yoshioka
  • Publication number: 20130172414
    Abstract: A pharmaceutical composition comprising levocarnitine and dobesilate is provided. Also provided are a method for regulating the level of serum creatinine and/or blood urea nitrogen and a method for treating and/or preventing the diseases influencing renal function, for example, including but not limiting to various primary, secondary nephritis, renal lesions, renal insufficiency, nephritic syndrome, even renal failure, uremia, as well as the complications induced by the diseases and/or disorders influencing renal function for example, such as cardiovascular diseases, diabetes and the like.
    Type: Application
    Filed: June 10, 2011
    Publication date: July 4, 2013
    Applicants: TIANJIN NANKAI SHARE PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD., XIZANG LINZHI PARKSON PHARMACEUTICAL CO., LTD., NANKAI SHARE PHARMACEUTICAL CO., LTD., LIAONING SEBEST PHARMACEUTICL CO., LTD.
    Inventors: Yong Wang, Xin Zhao, Mo Chen, Ning Tian
  • Publication number: 20130156855
    Abstract: One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 20, 2013
    Inventor: Aviv Ben-Menachem
  • Publication number: 20130137651
    Abstract: The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 30, 2013
    Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventor: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.